Instem achieves a major milestone, acquires all shares of Xybion from Banerjee Group LLC controlled by Dr. Pradip K. Banerjee
Xybion was founded in 1977 to support preclinical R&D and drug safety testing for regulatory submissions. In 2008, Banerjee Group LLC controlled by veteran life sciences R&D Executive and founding managing partner of Accenture's life sciences R&D business, acquired Xybion and completed further acquisitions of Amadeus solutions, Stelex and Vital Path from GE Healthcare and Autoscribe Informatics.
The core solution, Pristima TM, is an advanced and cloud-based SaaS study management platform tailored to facilitate primarily GLP preclinical research. Xybion also has solutions in the LIMS space through its Autoscribe TM brand, for R&D Quality Management (Xybion QMS TM), and an advisory services arm. Xybion's software solutions and consulting services serve customers on a global scale, with active customers in over 30 countries across 5 continents.
'The combination of these two companies effectively creates a 'new Instem' in the preclinical R&D space – a leader with unparallelled scale and talent enabling us to better focus on our mission to help our customers make discoveries, and to accelerate and advance their research programs. We will also now have more resources to devote to innovation and toward delighting customers. We believe this is a truly transformational development in the field of preclinical life sciences R&D. I also want to take this opportunity to welcome Xybion's employees to Instem and express how delighted I am that we are joining forces.' Vik Krishnan, CEO, Instem.
The acquisition of Xybion adds many new large and industry-leading customers in the pharmaceutical and CRO spaces.
The combination allows Instem to meet the needs of all life sciences users in preclinical study management. Instem is further supported in its mission with Xybion's experienced staff in this space. 'We are excited about the future after joining forces to solve complex R&D projects in the regulated GLP environment,' further said Mr. Krishnan.
About Instem
Instem is a leading supplier of SaaS platforms across Discovery, Study Management, Regulatory Submission and Clinical Trial Analytics. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Founded in the United Kingdom in 1969, Instem has deep roots internationally across North America, EMEA and APAC. Instem maintain a commercial and technical presence throughout these regions and pride ourselves on localized support for our diverse client base. Instem has been an ARCHIMED company since 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
CNBC
3 hours ago
- CNBC
Cramer's week ahead: Earnings from Palantir, Berkshire Hathaway, Disney and McDonald's
CNBC's Jim Cramer walked investors through another week of earnings season, honing in on reports from Palantir, Berkshire Hathaway, Disney and Eli Lilly. "We're still in earnings Hades, but at least it's getting a little cooler out there," he said. "That's right, we've now gotten over the hump of the big-time growth stocks, the hyperscalers, but there's plenty left." On Saturday, Cramer will be paying attention to earnings from Berkshire Hathaway, and he suggested things might be a little different with Greg Abel at the helm. If the report is good, Cramer said he bets the stock goes higher. Monday, Cramer is watching Palantir's report. He has called the company, which just landed a $10 billion Army contract, "the most controversial stock in the entire market." He said the data outfit has excited many on Wall Street. And he predicted the quarter will be "a total blowout," as it seems business is strong. Tuesday brings quarterly results from DuPont De Nemours, Caterpillar, Pfizer and Marriott. Cramer said it's important to see that DuPont's breakup is on track, because the parts are worth more than the whole for the chemical company. He suggested Caterpillar will post strong results as the equipment manufacturer rides the tailwinds of domestic infrastructure and reshoring. To Cramer, it's necessary that Pfizer sees some "really dramatic" results from clinical trials because the pharmaceutical giant's shareholder base is "getting very restive." Marriott is usually reliable, he continued, but said the hotel chain's stock tends to come down after earnings even if the results are good. Disney and McDonald's are set to report on Wednesday. Shares of the media titan have been climbing nicely, Cramer said, and he praised the streaming, theme park and cruise line business segments. He also said McDonald's is a buy at current levels, suggesting the company has improved as of late with new offerings for customers. Dutch Bros and E.l.f Beauty, two young "renegade" companies that have shaken up business in their respective sectors, will also report Wednesday, Cramer said. He added that he thinks they both have room to grow and take share. Thursday brings earnings from Eli Lilly. Cramer pointed out that its main competitor in the GLP-1 drug arena, Novo Nordisk, just posted a disappointing quarter. He wondered whether Novo Nordisk's results indicate that Eli Lilly has been taking share or if both companies are seeing a peak in their popular weight loss medication. He said both dynamics could be true. Warner Bros Discovery, MP Materials, Wynn Resorts and Pinterest are also set to report on Thursday. Cramer said he's waiting to hear how Warner Bros is reorganizing the company and paying down debt. He said he wants to learn about rare earth mineral miner MP Materials' deal with the U.S. government. He also said he's feeling positive about Wynn Resorts. Pinterest is likely to post a solid report, he continued, and said it's the most family-friendly advertising platform compared to its peers. Wendy's will post earnings on Friday, and Cramer said the previous quarter was weak. He suggested the sector is so competitive that there are no guarantees the burger chain will share good results. Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest The CNBC Investing Club Charitable Trust owns share of DuPont de Nemours, Disney and Eli Lilly.
Business Wire
5 hours ago
- Business Wire
General American Investors Files Certified Shareholder Report for Period Ended June 30, 2025
NEW YORK--(BUSINESS WIRE)--General American Investors Company, Inc., a closed-end investment company listed on the New York Stock Exchange (GAM), filed with the U.S. Securities and Exchange Commission (SEC) its Certified Shareholder Report (Form N-CSR) for the six-month period ended June 30, 2025. The Form N-CSR contains the Company's June 30, 2025 Semi-Annual Report and is available at the SEC's website: and the Company's website: The Semi-Annual Report is expected to be mailed to stockholders shortly. The Semi-Annual Report indicates that as of or for the six months ended: * After a distribution of $4.07 per share from net long-term capital gains and a dividend of $0.43 per share paid in December 2024 and a distribution of $0.25 per share from long-term capital gains paid in March 2025. Expand The largest stock holdings in the Company's portfolio as of June 30, 2025, included: Microsoft, Republic Services, Berkshire Hathaway, TJX Companies, and Amazon.
